Real-World Overall Response Rate and Other Outcomes Related to Originator and Biosimilar Rituximab in Patients with CLL or NHL in the United Kingdom

2021 Year in Review - Biosimilars —December 30, 2021



The results of a noninterventional, retrospective study showed that rituximab originator and the rituximab-abbs biosimilars yielded comparable efficacy and tolerability in the first-line treatment of patients with CLL and NHL, with rituximab-abbs use resulting in cost-savings.

A noninterventional, retrospective study assessed the real-world patient outcomes relating to effectiveness and tolerability of the rituximab originator and its biosimilar rituximab-abbs in the first-line treatment of patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) in the United Kingdom; the results of this study were presented at the 2021 American Society of Clinical Oncology Annual Meeting.

Data on patient characteristics, response to treatment, healthcare resource utilization, and costs were abstracted retrospectively via an online physician survey. UK-registered hematologists and oncologists reported on randomly selected patients aged 18 years from 4 cohorts with documented CLL or NHL who had received rituximab-abbs or rituximab as first-line immunotherapy (between January 1, 2018, and June 30, 2019). Patient outcomes data were provided from the first treatment to the last date of follow-up available in the medical records.

A total of 46 participating physicians identified 201 patients with CLL or NHL who were treated with rituximab or rituximab-abbs. In terms of efficacy outcomes, the overall response rate, 6-month progression-free survival, and 1-year survival were comparable for rituximab and rituximab-abbs in patients with CLL or NHL.

Across cohorts, the most common grade ≥3 adverse events were neutropenia, fatigue, anemia, and infusion reactions. Healthcare resource utilization was high but similar across cohorts, owing to drug costs, diagnostic testing, oncologist office visits, and day hospital admissions. Use of rituximab-abbs realized a mean annual savings of approximately £1,000 per patient, which was attributed to first-line treatment costs.

Based on the results of this noninterventional retrospective study, it was concluded that the rituximab originator and the rituximab-abbs biosimilar yielded comparable efficacy and tolerability in the first-line treatment of patients with CLL and NHL, with rituximab-abbs utilization resulting in cost-savings.

Source: McBride A, Daniel S, Driessen MT, et al. Real-world overall response rate and other outcomes related to originator and biosimilar rituximab in patients with chronic lymphocytic leukemia or non-Hodgkin’s lymphoma in the United Kingdom. J Clin Oncol. 2021;39(suppl_15):e18696.

Related Articles
Comparative Efficacy and Safety of the Bevacizumab Biosimilar MIL60 versus Bevacizumab Reference in Patients with Advanced or Recurrent Nonsquamous NSCLC
2021 Year in Review - Biosimilars
The results of a randomized, double-blind phase 3 study established the equivalence of bevacizumab reference to its biosimilar MIL60 in terms of clinical efficacy, safety, population pharmacokinetics, and immunogenicity in patients with nonsquamous NSCLC.
Cost-Effectiveness of Subcutaneous Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf for the Treatment of High-Risk, HER2-Positive Early Breast Cancer
2021 Year in Review - Biosimilars
Findings from modeling studies support adjuvant continuation of pertuzumab plus trastuzumab for patients achieving pathologic complete response among patients with high-risk, HER2-positive early breast cancer.
Same-Day Pegfilgrastim or PFG-cbqv Prophylaxis of Chemotherapy-Induced Neutropenia in Bendamustine plus Rituximab and CHOP±R Regimens in Patients with Lymphoma and CLL
2021 Year in Review - Biosimilars
Real-world outcomes from a retrospective, single-center study suggested that pegfilgrastim or its biosimilar pegfilgrastim-cbqv does not increase febrile neutropenia or delayed engraftment risk in patients with lymphoma and CLL and may be safe to use after administration of chemotherapy.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State